Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)

Inclusion Criteria: * Healthy male adults aged 19 to 50 years at the time of screening test * 55.0 kg ≤ Body weight ≤ 90.0 kg and 18.0 ≤ Body Mass Index (BMI) ≤ 27.0 * Written consent on voluntary decision of participation prior to the screening procedure after being fully informed of and completely understanding this study * Eligible to participate in the study at the discretion of the investigator by physical examination, laboratory test, and history taking, etc. Exclusion Criteria: * Current or history of clinically significant hepatic, renal, nervous, respiratory, endocrine, hemato-oncology, cardiovascular, urogenital, psychosis disorder * Current or history of gastrointestinal disorders or prior history of gastrointestinal surgery that may affect safety and PK/PD assessment of the study drug * Hypersensitivity or medical history of clinically significant hypersensitivity to a drug containing an ingredient of the investigational product (DWP16001), Dapagliflozin, Metformin or similar ingredient or other drugs (e.g., aspirin, antibiotics, etc.) * Clinical laboratory test values are outside the accepted normal range at screening * Other exclusive inclusion criteria, as defined in the protocol